Tau positron emission tomographic imaging in the lewy body diseases

JAMA Neurology

Volumn 73, Issue 11, 2016, Pages 1334-1341

  Gomperts, Stephen N ^a   Locascio, Joseph J ^a   Makaretz, Sara J ^a   Schultz, Aaron ^a   Caso, Christina ^a   Vasdev, Neil ^a   Sperling, Reisa ^a   Growdon, John H ^a   Dickerson, Bradford C ^a   Johnson, Keith ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLORTAUCIPIR F 18; PITTSBURGH COMPOUND B; TAU PROTEIN; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; AMYLOID BETA PROTEIN; ANILINE DERIVATIVE; CARBOLINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGE; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; FEMALE; HUMAN; INFERIOR TEMPORAL GYRUS; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIMODAL IMAGING; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PRIORITY JOURNAL; PROTEIN AGGREGATION; TERTIARY CARE CENTER; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; NEOCORTEX; PATHOPHYSIOLOGY; PROCEDURES;

AGED; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; CARBOLINES; COGNITIVE DYSFUNCTION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LEWY BODY DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOCORTEX; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; THIAZOLES;

EID: 84996968528     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.3338     Document Type: Article

References (51)

1. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 2001;102(4):355-363.
2. Jellinger KA, Seppi K,Wenning GK, PoeweW. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm (Vienna). 2002;109(3):329-339.
3. Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 2008;115(4):427-436.
4. Horvath J, Herrmann FR, Burkhard PR, Bouras C, Kövari E. Neuropathology of dementia in a large cohort of patients with Parkinson's disease. Parkinsonism Relat Disord. 2013;19(10):864-868.
5. Howlett DR, Whitfield D, Johnson M, et al. Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias. Brain Pathol. 2015;25(4):401-408.
6. Ruffmann C, Calboli FC, Bravi I, et al. Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol Appl Neurobiol. 2016;42(5): 436-450.
7. Gomperts SN. Imaging the role of amyloid in PD dementia and dementia with Lewy bodies. Curr Neurol Neurosci Rep. 2014;14(8):472.
8. Villemagne VL, Fodero-TavolettiMT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114-124.
9. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71(12):903-910.
10. Gomperts SN, Locascio JJ, Marquie M, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord. 2012;27(8):965-973.
11. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008; 79(12):1331-1338.
12. Kantarci K, Lowe VJ, Boeve BF, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging. 2012;33(9): 2091-2105.
13. Gomperts SN, Locascio JJ, Rentz D, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 2013;80(1):85-91.
14. Gomperts SN, Marquie M, Locascio JJ, Bayer S, Johnson KA, Growdon JH. PET radioligands reveal the basis of dementia in Parkinson's disease and dementia with Lewy bodies. Neurodegener Dis. 2016;16(1-2):118-124.
15. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol. 2012;71(5): 362-381.
16. Spillantini MG, GoedertM. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6): 609-622.
17. Braak H, Rüb U, Schultz C, Del Tredici K. Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. J Alzheimers Dis. 2006;9(3) (suppl):35-44.
18. Raskin J, Cummings J, Hardy J, Schuh K, Dean RA. Neurobiology of Alzheimer's disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Curr Alzheimer Res. 2015;12(8):712-722.
19. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42(3, pt 1): 631-639.
20. Serrano-Pozo A, Qian J, Monsell SE, Frosch MP, Betensky RA, Hyman BT. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol. 2013;72(12):1182-1192.
21. Walker L, McAleese KE, Thomas AJ, et al. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 2015;129(5):729-748.
22. Xia CF, Arteaga J, Chen G, et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9(6):666-676.
23. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34 (2):457-468.
24. Marquié M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5): 787-800.
25. Sander K, Lashley T, Gami P, et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias [published online February 16, 2016]. Alzheimers Dement.
26. McKeith IG, Dickson DW, Lowe J, et al; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863-1872.
27. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993;50(2): 140-148.
28. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3): 349-356.
29. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12): 1689-1707.
30. Hedden T, Van Dijk KRA, Becker JA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29(40):12686-12694.
31. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004;62(2):181-187.
32. Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med. 2011;12(5): 445-453.
33. National Alzheimer's Coordinating Center. UDS forms and documentation. http://www.alz .washington.edu/WEB/forms-uds.html. Published 2010. Accessed January 1, 2014.
34. Lang A, Fahn S. Assesment of parkinson's disease. In: Munstat TL, ed. Quantification of Neurologic Deficit. Boston, MA: Butterworths; 1989:285-309.
35. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5): 427-442.
36. Shoup TM, Yokell DL, Rice PA, et al. A concise radiosynthesis of the tau radiopharmaceutical, [18F]T807. J Labelled Comp Radiopharm. 2013;56 (14):736-740.
37. Becker JA, Hedden T, Carmasin J, et al. Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032-1042.
38. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528-1547.
39. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-119.
40. Marquie M, Locascio JJ, Rentz DM, et al. Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study. Alzheimers Res Ther. 2014;6(5-8):52.
41. Logan J, Fowler JS, Volkow ND,Wang G-J, Ding Y-S, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5): 834-840.
42. Greve DN, Salat DH, Bowen SL, et al. Different partial volume correction methods lead to different conclusions: An 18F-FDG-PET study of aging. Neuroimage. 2016;132:334-343.
43. Fischl B, Salat DH, van der Kouwe AJ, et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage. 2004;23(suppl 1):S69-S84.
44. Desikan RS, Cabral HJ, Hess CP, et al; Alzheimer's Disease Neuroimaging Initiative. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain. 2009;132(pt 8):2048-2057.
45. Schöll M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971-982.
46. Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139(pt 5):1551-1567.
47. Schwarz AJ, Yu P, Miller BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139(pt 5):1539-1550.
48. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389-404.
49. Haggerty T, Credle J, Rodriguez O, et al. Hyperphosphorylated tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease. Eur J Neurosci. 2011;33(9):1598-1610.
50. Credle JJ, George JL, Wills J, et al. GSK-3β dysregulation contributes to Parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein. Cell Death Differ. 2015;22(5):838-851.
51. Kramer ML, Schulz-SchaefferWJ. Presynaptic α-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci. 2007;27(6):1405-1410.